Slade Michael, Goldsmith Scott, Romee Rizwan, DiPersio John F, Dubberke Erik R, Westervelt Peter, Uy Geoffrey L, Lawrence Steven J
Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12629. Epub 2016 Dec 28.
The use of T-cell replete haploidentical hematopoietic cell transplant (haplo-HCT) has increased substantially since the introduction of post-transplant cyclophosphamide (PTCy) regimens. Limited data exist concerning infectious complications of haplo-HCT utilizing mobilized peripheral blood (PB) hematopoietic cells.
This retrospective cohort study included all adult patients at our institution undergoing PB haplo-HCT with PTCy between June 2009 and June 2015. Infections were microbiologically confirmed. Invasive fungal infections (IFI) classified as "proven" or "probable" by standard definitions were included.
In total, 104 patients were identified. Median follow-up was 218 days (range: 6-1576). A total of 322 episodes of infection were recorded. Eighty-nine percent of patients experienced at least one infection. Median time to first infection was 22 days. Patients experiencing at least one bacterial, viral, and IFI were 62%, 72%, and 6%, respectively. The majority (69%) of bacterial infections were caused by enteric organisms. Seven cases of Staphylococcus aureus infection were recorded, with one bacteremia case. Cytomegalovirus (CMV) viremia occurred in 54/71 (76%) at-risk patients at a median time of 24 days. Sixteen (15%) patients developed CMV disease. Nineteen percent (20/104) of patients developed BK polyomavirus-associated cystitis. Six (6%) patients experienced a total of seven IFI. Infection was the primary cause of death for 12% (6/51) of patients and was a secondary cause for 41%.
In PB haplo-HCT patients, a high incidence of CMV viremia and disease was observed. Infections with enteric bacteria were common. Fungal and staphylococcal infections were uncommon. Further studies are needed to compare infectious complications in haplo-HCT with other transplant modalities.
自采用移植后环磷酰胺(PTCy)方案以来,T细胞充足的单倍体相合造血细胞移植(haplo-HCT)的应用显著增加。关于利用动员外周血(PB)造血细胞进行haplo-HCT的感染并发症的数据有限。
这项回顾性队列研究纳入了2009年6月至2015年6月期间在本机构接受PB haplo-HCT并使用PTCy的所有成年患者。感染经微生物学确诊。包括根据标准定义分类为“确诊”或“可能”的侵袭性真菌感染(IFI)。
共确定了104例患者。中位随访时间为218天(范围:6 - 1576天)。共记录了322次感染发作。89%的患者经历了至少一次感染。首次感染的中位时间为22天。经历至少一次细菌、病毒和IFI感染的患者分别为62%、72%和6%。大多数(69%)细菌感染由肠道微生物引起。记录到7例金黄色葡萄球菌感染,其中1例为菌血症病例。54/71(76%)例有感染风险的患者发生了巨细胞病毒(CMV)血症,中位时间为24天。16例(15%)患者发生了CMV疾病。19%(20/104)的患者发生了BK多瘤病毒相关性膀胱炎。6例(6%)患者共经历了7次IFI。感染是12%(6/51)患者的主要死亡原因,是41%患者的次要死亡原因。
在PB haplo-HCT患者中,观察到CMV血症和疾病的高发生率。肠道细菌感染很常见。真菌和葡萄球菌感染不常见。需要进一步研究以比较haplo-HCT与其他移植方式的感染并发症。